Literature DB >> 21142621

The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain.

Anna Papa1, Evangelia Papadimitriou, Iva Christova.   

Abstract

The Crimean-Congo haemorrhagic fever virus (CCHFV) is a 3-segmented RNA virus, which causes disease with a high fatality rate in humans. An inactivated suckling mouse brain-derived vaccine is used in Bulgaria for protection against CCHF. Strain V42/81 is currently used for the vaccine preparation. As the M-RNA segment plays a major role in the immune response, the full-length M segment sequence of the V42/81 strain was characterized. A great genetic diversity was observed among CCHFV strains. In order to gain an insight into the topology of the strain in the CCHFV phylogenetic trees, the full-length S and partial L segments were additionally sequenced and analyzed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21142621     DOI： 10.3109/00365548.2010.540036

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  23 in total

1.  Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus.

Authors:  S M Ghiasi; A H Salmanian; S Chinikar; S Zakeri
Journal:  Clin Vaccine Immunol       Date:  2011-10-19

Review 2.  Crimean-Congo hemorrhagic fever: an overview.

Authors:  Serkan Oncü
Journal:  Virol Sin       Date:  2013-07-22       Impact factor: 4.327

3.  An update on crimean congo hemorrhagic Fever.

Authors:  Suma B Appannanavar; Baijayantimala Mishra
Journal:  J Glob Infect Dis       Date:  2011-07

4.  Crimean-Congo hemorrhagic fever: epidemiological trends and controversies in treatment.

Authors:  Helena C Maltezou; Anna Papa
Journal:  BMC Med       Date:  2011-12-08       Impact factor: 8.775

5.  Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses.

Authors:  Stuart D Dowall; Victoria A Graham; Emma Rayner; Laura Hunter; Robert Watson; Irene Taylor; Antony Rule; Miles W Carroll; Roger Hewson
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

Review 6.  Development of vaccines against Crimean-Congo haemorrhagic fever virus.

Authors:  Stuart D Dowall; Miles W Carroll; Roger Hewson
Journal:  Vaccine       Date:  2017-07-04       Impact factor: 3.641

7.  Seroprevalence of Crimean-Congo hemorrhagic fever virus, Bulgaria.

Authors:  Iva Christova; Teodora Gladnishka; Evgenia Taseva; Nikolay Kalvatchev; Katerina Tsergouli; Anna Papa
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

8.  Immunization of knock-out α/β interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine.

Authors:  Nurettin Canakoglu; Engin Berber; Sukru Tonbak; Mustafa Ertek; Ibrahim Sozdutmaz; Munir Aktas; Ahmet Kalkan; Aykut Ozdarendeli
Journal:  PLoS Negl Trop Dis       Date:  2015-03-11

9.  Sheep and goats as indicator animals for the circulation of CCHFV in the environment.

Authors:  Isolde Schuster; Marc Mertens; Slavcho Mrenoshki; Christoph Staubach; Corinna Mertens; Franziska Brüning; Kerstin Wernike; Silke Hechinger; Kristaq Berxholi; Dine Mitrov; Martin H Groschup
Journal:  Exp Appl Acarol       Date:  2015-12-24       Impact factor: 2.132

10.  A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.

Authors:  S D Dowall; K R Buttigieg; S J D Findlay-Wilson; E Rayner; G Pearson; A Miloszewska; V A Graham; M W Carroll; R Hewson
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.